Clinical Trial Update: Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated first-line therapy with docetaxel plus cetuximab or docetaxel plus bortezomib in patients with Stage IIIB or Stage IV non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Adenosquamous Cell Lung Cancer
• Large Cell Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• Cetuximab (cetuximab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer | Phase 2 | Status: COMPLETED